France, Nov. 18 -- Project Id: 76993
Description: Grant agreement ID: 633413
Project website
Status
Ongoing project
Start date
1 September 2015
End date
30 September 2021
Funded under:
H2020-EU.3.1.3.
Overall budget:
€ 6 510 741,95
EU contribution
€ 5 980 435
Objective
Amyotrophic Lateral Sclerosis (ALS) is a fatal degenerative disorder of the brain and spinal cord affecting some 40,000 individuals in Europe, causing 11,000 deaths each year. Our pioneering work on riluzole showed that it is possible to modify ALS progression but all subsequent trials of potential neuroprotective agents have failed. Thus, drug development in ALS, including trial design, patient selection, and outcome measures must be re-engineere...